{
    "clinical_study": {
        "@rank": "8325", 
        "arm_group": {
            "arm_group_label": "Metastatic prostate cancer", 
            "arm_group_type": "Experimental", 
            "description": "Near infrared (NIR) emissive nanotechnology"
        }, 
        "brief_summary": {
            "textblock": "This is a minimal risk correlative clinical blood-drawing protocol. The objective of this\n      lead in pilot component is to determine whether Circulating Tumor Cells (CTC's) can be\n      captured using the novel mesenchymal-marker based Near Infrared-Emissive Polymersomes\n      (NIR-EPs), the PSMA-based NIR-EP, and the epithelial EpCAM-based NIR-EP.   If successful,\n      the capture method will be evaluated further in the larger comparative study."
        }, 
        "brief_title": "Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplastic Cells, Circulating", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically confirmed diagnosis of adenocarcinoma of the prostate\n\n          -  Clinical or radiographic evidence of metastatic disease\n\n          -  Evidence of disease progression on androgen deprivation therapy (ADT) as evidenced by\n             either of the following in the past:\n\n               1. Two consecutive PSA levels greater than the PSA nadir achieved on ADT, separated\n                  by greater than one week\n\n               2. Radiographic evidence of disease progression as defined by new bone scan lesions\n                  or soft tissue/visceral metastases >2 cm in diameter.\n\n               3. Clinical progression as determined by the treating physician.\n\n          -  Age greater than 18 years.\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  History of intercurrent or past medical or psychiatric illness that would make\n             participation in a blood drawing protocol difficult or not feasible at the discretion\n             of the principal investigator or co-investigator(s)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022904", 
            "org_study_id": "Pro00037349"
        }, 
        "intervention": {
            "arm_group_label": "Metastatic prostate cancer", 
            "intervention_name": "Near infrared (NIR) emissive nanotechnology", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "prostate cancer", 
            "metastatic", 
            "castrate resistant"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "michael.goodin@dm.duke.edu", 
                "last_name": "Michael Goodin", 
                "phone": "919-668-8375"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Andrew Armstrong, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Development of a Novel Method to Detect Prostate Cancer Circulating Tumor Cells (CTCs) Based on Epithelial-mesenchymal Transition Biology", 
        "overall_contact": {
            "email": "michael.goodin@dm.duke.edu", 
            "last_name": "Michael Goodin", 
            "phone": "919-668-8375"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Andrew Armstrong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Non-detection rate of CTC's in men with CRPC will be measured at baseline, month 3, and at progression", 
            "measure": "Change in Non-detection rate of CTC's in men with CRPC", 
            "safety_issue": "No", 
            "time_frame": "at baseline, month 3, and progression (up to 18 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Calculate for each patient the number of CTC's detected by each capture method (novel and standard).", 
                "measure": "Median number of CTC's detected by each capture method", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "description": "For each method, we will plot the change across time (baseline, cycle 3, and at progression) in the median number of CTC's for each method (novel and standard).", 
                "measure": "Change in median number of CTC's for each method", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with presenting clinical stage", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with sites of metastatic disease", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with Gleason sum", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with PSA kinetics", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with therapies", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with overall survival", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }, 
            {
                "measure": "Correlation of CTC enumeration with response to therapy", 
                "safety_issue": "No", 
                "time_frame": "at baseline, month 3, and progression (up to 18 months)"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Defense", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}